ClinicalTrials.gg
RecruitingNCT04096625Updated Sep 28, 2023

Enhancement of a Psychotherapeutic Intervention Through Transcranial Direct Current Stimulation (tDCS)

An interventional study of Active tDCS and Assertiveness Training Program (ATP) in Psychiatric Disorder, sponsored by Psychiatric University Hospital, Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Psychiatric University Hospital, Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Transcranial Direct Current Stimulation (tDCS), is a neuromodulatory technique, that is safe, well-tolerated, easy to administer and fairly inexpensive. Results from tDCS trials involving participants with several neuropsychiatric disorders, including major depression, bipolar disorder, schizophrenia and substance use disorder are encouraging. The clinical effects of tDCS are broad; the underlying condition, the areas stimulated together with the type and duration of stimulation are important factors. In patients with neuropsychiatric conditions, a reduction of symptoms, an enhancement of neurocognitive functions together with an overall improvement in functionality and wellbeing have been consistently reported. These effects emerge during the stimulation period, in the weeks after stimulation, the effects seem to peak and consolidate further. tDCS appears to enhance the effects of other interventions as well; however, to date, there have been no studies into the effects of using tDCS as an add-on intervention to psychotherapy on symptoms and wellbeing

02

Conditions studied

  • Psychiatric Disorder

Browse trials for

Keywords

  • Brain Stimulation, tDCS, Psychotherapy, Psychiatric Disorder
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Psychiatric University Hospital, Zurich is the lead sponsor of 22 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are competent to give , as determined by the referring physician or psychiatrist.
  • German language proficiency as a native speaker or level B1
  • A psychiatric diagnosis according to ICD-10;
  • Three or more psychiatric hospitalizations in the past 12 months; or
  • A cumulative length of stay over 40 days; or
  • Referral for further treatment to our treatment unit.

Exclusion criteria

Exclusion Criteria:

  • Concomitant group psychotherapeutic intervention.
  • Current neurological disorder.
  • Current cardiovascular disorder.
  • Current respiratory disorder.
  • Current substance use or withdrawal.
  • Epilepsy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Active tDCS

    Active tDCS will be delivered at 2mA for 20 minutes.

    Device: Active tDCS · Behavioral: Assertiveness Training Program (ATP) · Device: Sham tDCS

  • Sham comparator
    Sham tDCS

    Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).

    Device: Active tDCS · Behavioral: Assertiveness Training Program (ATP) · Device: Sham tDCS

Interventions

  • DeviceActive tDCS

    Active tDCS will be delivered at 2mA for 20 minutes.

  • BehavioralAssertiveness Training Program (ATP)

    The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.

  • DeviceSham tDCS

    Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).

06

What researchers measure

Primary outcomes

  1. Psychopathological Assessment

    Symptom Questionnaire

    Time frame: Change: Baseline, 3, 6 weeks, 6 and 12 months

Secondary outcomes

  1. Insecurity- Self-confidence

    Symptom Questionnaire

    Time frame: Change: Baseline, 3, 6 weeks, 6 and 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2025, 26 months after the start.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 26 months is below that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Sep 20, 2019
StartActual
Sep 1, 2023
Primary completionEst.
Nov 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04096625
Lead sponsor
Psychiatric University Hospital, Zurich
Responsible party
Stephan T. Egger (Senior Psychiatrists, Psychiatric University Hospital, Zurich) — Principal investigator
First posted
Sep 20, 2019
Start date
Sep 1, 2023
Primary completion
Nov 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 28, 2023

Study contacts

Stephan T. Egger, MD
Contact
stephan.egger@puk.zh.ch
+41523049340
Stephan T. Egger, MD
principal investigator · Psychiatric University Hospital of Zurich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion